Open access
118
Views
0
CrossRef citations to date
0
Altmetric
Original Research
Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
Marco Bellone1 Department of Health Economics and Outcome Research, AdRes Health Economics and Outcomes Research, Turin, ItalyCorrespondence[email protected]
View further author information
, View further author information
Lorenzo Pradelli1 Department of Health Economics and Outcome Research, AdRes Health Economics and Outcomes Research, Turin, Italy
https://orcid.org/0000-0002-7648-8917View further author information
Stefano Molica2 Dipartimento Onco-ematologico, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, ItalyView further author information
, Adele Emanuela De Francesco3 Hospital Pharmacy, Mater Domini Azienda Ospedaliero Universitaria, Catanzaro, ItalyView further author information
, Daniela Ghislieri4 Market Access Department, Roche SpA, Monza, ItalyView further author information
, Emanuele Guardalben5 Medical Department, Roche SpA, Monza, ItalyView further author information
& Antonietta Caputo4 Market Access Department, Roche SpA, Monza, ItalyView further author information
show all
Pages 661-671
|
Published online: 22 Jul 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.